Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674281 | 0.82 | MAPT (0.51) | ALDH1A1L3MBTL1GAARAB9ASMN1; SMN2 | |
| SCHEMBL1682693 | 0.74 | KMT2A (0.36) | ALDH1A1KDM4EGAARAB9ASMN1; SMN2 | |
| SCHEMBL1539571 | 0.72 | HCAR2 (0.44) | ALDH1A1KDM4EGAARAB9APRKAG1 | |
| SCHEMBL6786585 | 0.72 | ALDH1A1 (0.63) | ALDH1A1PTGER1KDM4EACHEHPGDS | |
| SCHEMBL1529600 | 0.71 | AKT1 (0.51) | ALDH1A1KDM4EGAA | |
| SCHEMBL25527328 | 0.71 | HTR2A (0.38) | ALDH1A1KDM4E | |
| SCHEMBL676174 | 0.71 | ALDH1A1 (0.51) | ALDH1A1PTGER1KDM4EACHEHPGDS | |
| SCHEMBL1815261 | 0.71 | ALDH1A1 (0.55) | ALDH1A1PTGER1KDM4EACHEHPGDS | |
| SCHEMBL17130078 | 0.70 | GPR35 (0.39) | ALDH1A1KDM4EGAARAB9ASMN1; SMN2 | |
| SCHEMBL1529864 | 0.70 | DAO (0.45) | ALDH1A1KDM4EGAARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| EP-2303852-A2 | INHIBITORS OF AKT ACTIVITY | GlaxoSmithKline LLC (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009158374-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, PIK3CA | ALDH1A1 4692/4885PTGER1 3477/4885KDM4E 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.